About this episode

This episode features an interview discussing new mechanisms related to neutrophils and immune thrombocytopenia in the context of immune checkpoint inhibitors.

In this week's episode of the Blood podcast, editor Dr. James Griffin interviews Drs. Christian Gorzelanny and Rebecca Leaf on their latest articles published in this week's issue of Blood . Dr. Gorzelanny discusses compelling evidence for a new mechanism that amplifies their proinflammatory actions in " Lipid nanotubes unmask neutrophils for complement attack ", demonstrating the pathological role of this process in a range of inflammatory disorders in order to stimulate intense study of how to regulate nanotube formation for therapeutic benefit. In " Immune thrombocytopenia in patients treated with immune checkpoint inhibitors " Dr. Leaf and colleagues define the incidence, clinical features, and outcomes of ICI-induced immune thrombocytopenia. Showing that ICI-induced immune thrombocytopenia is associated with excess mortality, these data should provide an impetus to greater recognition and to protocolization of effective interventions.

People in this episode

Host: Dr. James Griffin

Guests: Dr. Christian Gorzelanny, Dr. Rebecca Leaf

Topics covered

• neutrophils
• immune thrombocytopenia
• immune checkpoint inhibitors
• inflammatory disorders
• therapeutic interventions

Keywords

• neutrophils
• immune thrombocytopenia
• immune checkpoint inhibitors
• inflammatory disorders
• therapeutic benefit
• excess mortality
• clinical features

Mentioned in this episode

Organizations: Blood

Books & works: Lipid nanotubes unmask neutrophils for complement attack, Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

More episodes of Blood Podcast

• Pathophysiology of ANKRD26-related thrombocytopenia and B-ALL recurrence after blinatumomab · April 23, 2026 · 19 min
• Real-world availability of CAR T-cell therapies · April 16, 2026 · 10 min
• Consequences of p53 loss and Gastrin for aGVHD of the Stomach · April 9, 2026 · 20 min
• Review Series on Myeloproliferative Neoplasms · April 2, 2026 · 26 min
• CH in children with SCD and Asciminib for CML in the ASC4FIRST trial · March 26, 2026 · 14 min
• Hepcidin-DMT1 interaction and GPRC5D-targeting bispecific antibody for MM · March 12, 2026 · 16 min

Explore listener stats, chart rankings, contacts and more on the Blood Podcast podcast page.